GALT
Galectin Therapeutics Inc
4.10$
-2.2%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +12.5% | +0.0% | +0.0% | +0.0% | +11.1% | +0.0% | -80.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -200.0% | – | – | |
| – | +6.4% | -2.1% | +21.8% | -22.6% | +46.3% | -41.6% | -49.7% | -19.9% | -26.0% | +15.4% | -4.3% | – | |
| – | -7.0% | +19.6% | -7.3% | -0.5% | -10.3% | +7.1% | -3.4% | +16.3% | -9.8% | +28.9% | +0.1% | – | |
| – | +4.3% | +0.9% | +17.0% | -19.7% | +37.1% | -36.5% | -41.4% | -9.2% | -19.8% | +21.2% | -2.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.4% | +24.2% | +20.6% | +17.7% | +15.5% | +1.1% | +4.7% | -0.3% | +6.5% | +2.5% | +0.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -371.9% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.